Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $143.4 million.

  • Cartesian Therapeutics' Cash & Current Investments fell 3458.7% to $143.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.4 million, marking a year-over-year decrease of 3458.7%. This contributed to the annual value of $212.6 million for FY2024, which is 17643.64% up from last year.
  • Cartesian Therapeutics' Cash & Current Investments amounted to $143.4 million in Q3 2025, which was down 3458.7% from $160.3 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Cash & Current Investments ranged from a high of $219.2 million in Q3 2024 and a low of $76.9 million during Q4 2023
  • For the 5-year period, Cartesian Therapeutics' Cash & Current Investments averaged around $137.2 million, with its median value being $138.7 million (2021).
  • As far as peak fluctuations go, Cartesian Therapeutics' Cash & Current Investments plummeted by 4564.2% in 2023, and later soared by 17643.64% in 2024.
  • Cartesian Therapeutics' Cash & Current Investments (Quarter) stood at $128.1 million in 2021, then increased by 5.11% to $134.6 million in 2022, then crashed by 42.86% to $76.9 million in 2023, then soared by 176.44% to $212.6 million in 2024, then tumbled by 32.56% to $143.4 million in 2025.
  • Its Cash & Current Investments stands at $143.4 million for Q3 2025, versus $160.3 million for Q2 2025 and $180.4 million for Q1 2025.